Branched Diepoxide Compounds for the Treatment of Inflammatory Disorders

• US 20100324133A1
• Filed: 07/07/2010
• Published: 12/23/2010
• Est. Priority Date: 01/07/2008
• Status: Abandoned Application

• Current Assignee: Dennis C. Liotta
• Original Assignee: Dennis C. Liotta
• Inventors: Liotta, Dennis C.
• Application Number:
  US12/831,672
• Publication Number:
  US 20100324133A1
• Time in Patent Office: Days
• US Class Current: 514/475
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 303/08 with hydrocarbon radicals, substituted by halogen atoms, nitro radicals or nitroso radicals
• CPC Class Codes: C07D 303/32 by aldehydo- or ketonic radicals

Abstract

The present invention provides certain diepoxide carbocyclic compounds wherein at least one carbocyclic ring carbon includes two non-epoxide substituents, and pharmaceutical compositions containing the same, for the treatment or prophylaxis of inflammatory, autoimmune and hyper- or abnormally proliferative diseases and disorders.

Claims

1. A compound of the formula (I) or (II):

2. The compound of claim 1, wherein the compound has the formula (I).

3. The compound of claim 1, wherein the compound has the formula (II).

4. The compound of claim 1, wherein A, B, D and E are O.

5. The compound of claim 1, wherein R^1′

, R^2′

, R^3′

and R^4′

are independently —

OH, —

OR⁹, —

NH₂, —

NHR⁹, or —

N(R⁹)₂.

6. The compound of claim 1, wherein R¹, R², R⁴, R⁵ and R⁶ are independently hydrogen or alkyl.

7. The compound of claim 1, wherein R⁵ and R⁶ are hydrogen.

8. The compound of claim 1, wherein R³ is hydrogen.

9. The compound of claim 1, wherein R⁴ is alkyl.

10. The compound of claim 1, wherein:

R¹ and R² are independently hydrogen or alkyl;

R⁴ is hydrogen or alkyl;

R⁵ and R⁶ are hydrogen; and

A, B, D and E are O.

11. The compound of claim 10, wherein the compound has the formula (I), and R^1′

and R^2′

are independently OH or NH₂.

12. The compound of claim 10, wherein the compound has the formula (II), and R^3′

and R^4′

are independently OH or NH₂.

13. The compound of claim 11, wherein R¹ is cyclohexyl, isopropyl or tert-butyl.

14. The compound of claim 1, wherein the compound has the structure

15. The compound of claim 1, wherein the compound has the structure

16. A pharmaceutical composition for the treatment or prophylaxis of an autoimmune, inflammatory or proliferative disorder comprising an effective treatment amount of the compound of claim 1 in combination with a pharmaceutically acceptable carrier.

17. A method for the treatment of an autoimmune or inflammatory disease in a patient comprising administering to the patient with an autoimmune or inflammatory disease an effective amount of a compound of claim 1, optionally with a pharmaceutically acceptable carrier.

18. A method for the treatment of abnormal cell proliferation in a patient comprising administering to the patient with an autoimmune or inflammatory disease an effective amount of a compound of claim 1, optionally with a pharmaceutically acceptable carrier.

19. The method of claim 17, wherein the abnormal cell proliferation is cancer.

20. A pharmaceutical composition for the treatment or prophylaxis of an autoimmune, an inflammatory or a proliferative disorder comprising an effective treatment amount of the compound of claim 1 in combination with another active agent and a pharmaceutically acceptable carrier.

21. A method for the treatment or prophylaxis of an autoimmune or inflammatory disease in a patient comprising administering to the patient with an autoimmune or inflammatory disease an effective amount of a compound of claim 1 in combination with one or more other active agent(s), optionally with a pharmaceutically acceptable carrier.

22. A method for the treatment or prophylaxis of abnormal cell proliferation in a patient comprising administering to the patient with a proliferative disorder an effective amount of a compound of claim 1 in combination with one or more other active agent(s), optionally with a pharmaceutically acceptable carrier.